<DOC>
	<DOCNO>NCT01666535</DOCNO>
	<brief_summary>The investigator compare immunogenicity influenza vaccine adult child inflammatory bowel disease time vaccine relation maintenance infliximab dosing . The primary objective compare proportion IBD patient maintenance infliximab mount serologic protection component influenza vaccination patient vaccinate day infliximab infusion ( Day 0 4 ) patient vaccinate mid-point infliximab infusion ( Day 21 28 ) . Serologic protection define hemagglutination-inhibition titer ≥ 1:40 . The secondary objective compare proportion IBD patient mount immunogenic response ( ≥ 4-fold increase pre post-vaccination titer ) component influenza vaccination patient vaccinate day infliximab infusion vaccinate mid-point .</brief_summary>
	<brief_title>Infliximab IBD Influenza Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis IBD establish accepted criterion On maintenance infliximab administer every 6 8 week ( already receive least 6 week infliximab ) Between age 9 60 year 1 . Pregnancy 2 . Hypersensitivity reaction previous dose influenza vaccine 3 . Known hypersensitivity egg chicken component influenza vaccine</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Immune response</keyword>
	<keyword>Remicade ( infliximab )</keyword>
	<keyword>Inflammatory bowel disease</keyword>
</DOC>